Results 211 to 220 of about 402,235 (309)

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Effect of pomegranate polyphenols on lipids metabolism in patients with myocardial infarction: a double-blind placebo controlled trial

, 2019
Rahul Goyal, Monika Pathania, S. Nagtilak, Vijay Thawani, S. Jindal   +4 more
openalex   +2 more sources

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Placebo Effect in the Treatment of Patellar Tendinopathy and Its Influencing Factors: Systematic Review With Meta-analysis and Meta Regression of Randomized Controlled Trials. [PDF]

Orthop J Sports Med
Previtali D, Albanese J, Romandini I, Merli G, Taraballi F, Filardo G.   +5 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Comparison of oral zinc supplement and placebo effect in improving the T-cells regeneration in patients undergoing autologous hematopoietic stem cell transplantation: Clinical trial study. [PDF]

Medicine (Baltimore)
Nikoonezhad M, Zavaran Hosseini A, Hajifathali A, Parkhideh S, Shadnoush M, Shakiba Y, Zahedi H.   +6 more
europepmc   +1 more source

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source

Magnitude of the Digital Placebo Effect and Its Moderators on Generalized Anxiety Symptoms: Systematic Review and Meta-Analysis.

J Med Internet Res
Hosono T, Tsutsumi R, Niwa Y, Kondoh M.
europepmc   +1 more source

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

, 2020

openalex   +1 more source